AcquisitionOther
Graphite Bio, Inc. acquired target
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Graphite Bio, Inc. -> target · $225 million
I am pleased to announce our merger with Graphite Bio, allowing us to create a publicly traded company focused on the advancement of LENZs lead programs, LNZ100 and LNZ101 for the treatment of presbyopia.
Open source record (SEC) ↗